Lakefront Biotherapeutics - Sponsored ADR (LKFT) vs Mesoblast Limited (MESO)

Lakefront Biotherapeutics - Sponsored ADR and Mesoblast Limited are both Biotechnology companies. Lakefront Biotherapeutics - Sponsored ADR and Mesoblast Limited are of similar size ($2.0B and $2.0B). Mesoblast Limited grew revenue faster over the last twelve months: −26.5% against −52.2%. Lakefront Biotherapeutics - Sponsored ADR has the higher net margin (−6.81% vs −1,091.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Lakefront Biotherapeutics - Sponsored ADR leads on 11 and Mesoblast Limited on 3.

Valuation

Metric LKFT MESO Biotechnology median
P/E n/m n/m 7.88
P/S 6.86 156.77 11.47
P/B 0.51 2.05 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 1.59 n/m 0.74
EV/Sales (2.35) 156.35 10.73
Earnings yield (0.97%) (7.41%) (28.84%)
Free cash flow yield (30.82%) (8.05%) (23.03%)

Profitability

Metric LKFT MESO Biotechnology median
Gross margin 89.75% (269.72%) 65.16%
Operating margin (90.11%) (826.28%) 0.00%
Net margin (6.81%) (1,091.71%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 0.00% (57.72%)
Return on assets 0.00% 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric LKFT MESO Biotechnology median
Revenue growth (TTM) (52.22%) (26.54%) 5.64%
EPS growth (last fiscal year) 355.37% 48.24% —
Revenue growth, 5-year CAGR 15.75% 74.39% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LKFT MESO Biotechnology median
Debt to equity 0.00 0.22 0.00
Current ratio 32.84 1.58 4.73
Net debt to EBITDA (8.53) (0.67) 0.96

Dividend

Metric LKFT MESO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric LKFT MESO Biotechnology median
Market cap 1.99b 2.01b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack